In its upcoming report, Incyte (INCY) is predicted by Wall Street analysts to post quarterly earnings of $1.58 per share, reflecting an increase of 49.1% compared to the same period last year.

Incyte (INCY) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives ...

The Sydney funnel-web spider has extremely dangerous venom, but according to a new study this spider is actually three different species — one of which, the "Newcastle big boy," is much larger.

Incyte's robust growth, led by JAKAFI and OPZELURA, is set to increase with new product launches of MONJUVI, ZYNZY, and NIKTIMVO in 2025. Analysts expect Incyte's revenues to grow by ~10% annually ...

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation ...